Genetic analysis of new 16s rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1719-1724

  Nessar, Rachid ^a,b   Reyrat, Jean Marc ^a,b   Murray, Alan ^c,d   Gicquel, Brigitte ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR   (France)

^d MASSEY UNIVERSITY   (New Zealand)

Author keywords

Antibiotic resistance; Evolution; Fitness

Indexed keywords

2 DEOXYSTREPTAMINE; ALANINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CYSTEINE; GUANINE; KANAMYCIN; RNA 16S; THREONINE;

ARTICLE; BACTERIAL COUNT; BACTERIAL GENE; BACTERIUM ISOLATE; CONTROLLED STUDY; DOMINANT INHERITANCE; ESCHERICHIA COLI; GENE MUTATION; GENE SEQUENCE; GENE VECTOR; GENETIC ANALYSIS; HETERODUPLEX ANALYSIS; HETEROZYGOTE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUTANT; MYCOBACTERIUM ABSCESSUS; NONHUMAN; PHENOTYPE; RECESSIVE INHERITANCE; SUBSTITUTION REACTION; WILD TYPE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; GENES, DOMINANT; GENES, RECESSIVE; GENES, RRNA; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; POINT MUTATION; RNA, BACTERIAL; RNA, RIBOSOMAL, 16S; SELECTION, GENETIC;

EID: 79960458842     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr209     Document Type: Article

References (34)

1. Brown-Elliott BA, Wallace RJ Jr Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15: 716-46.
2. De Groote MA, Huitt G. Infections due to rapidly growing mycobacteria. Clin Infect Dis 2006; 42: 1756-63.
3. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
4. Lowry PW, Jarvis WR, Oberle AD et al. Mycobacterium chelonae causing otitis media in an ear-nose-and-throat practice. N Engl J Med 1988; 319: 978-82.
5. Ozluer SM, De'Ambrosis BJ. Mycobacterium abscessus wound infection. Australas J Dermatol 2001; 42: 26-9.
6. Medjahed H, Gaillard JL, Reyrat JM. Mycobacterium abscessus: a new player in the mycobacterial field. Trends Microbiol 2010; 18: 117-23.
7. Griffith DE. The talking Mycobacterium abscessus blues. Clin Infect Dis 2011; 52: 572-4.
8. Petrini B. Mycobacterium abscessus: an emerging rapid-growing potential pathogen. APMIS 2006; 114: 319-28.
9. Ripoll F, Pasek S, Schenowitz C et al. Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One 2009; 4: e5660.
10. Nash KA, Brown-Elliott BA, Wallace RJ Jr A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-76.
11. Wallace RJ Jr, Meier A, Brown BA et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996; 40: 1676-81.
12. Prammananan T, Sander P, Brown BA et al. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis 1998; 177: 1573-81.
13. Kotra LP, Haddad J, Mobashery S. Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 2000; 44: 3249-56.
14. Chen LF, Kaye D. Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Infect Dis Clin North Am 2009; 23: 1053-75.
15. Hobbie SN, Pfister P, Brull C et al. Analysis of the contribution of individual substituents in 4,6-aminoglycoside-ribosome interaction. Antimicrob Agents Chemother 2005; 49: 5112-8.
16. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd ed. New York: Cold Spring Harbor Laboratory Press, 1989.
17. Catherinot E, Clarissou J, Etienne G et al. Hypervirulence of a rough variant of the Mycobacterium abscessus type strain. Infect Immun 2007; 75: 1055-8.
18. Cortes MA, Nessar R, Singh AK. Laboratory maintenance of Mycobacterium abscessus. Curr Protoc Microbiol 2010; Chapter 10: Unit 10D 1.
19. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 3192-7.
20. Pelicic V, Reyrat JM, Gicquel B. Expression of the Bacillus subtilis sacB gene confers sucrose sensitivity on mycobacteria. J Bacteriol 1996; 178: 1197-9.
21. Suzuki Y, Katsukawa C, Tamaru A et al. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 1998; 36: 1220-5.
22. Howard NS, Gomez JE, Ko C et al. Color selection with a hygromycin-resistance-based Escherichia coli-mycobacterial shuttle vector. Gene 1995; 166: 181-2.
23. Sander P, Springer B, Prammananan T et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 2002; 46: 1204-11.
24. Wallace RJ Jr, Hull SI, Bobey DG et al. Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Evidence is based on plasmid analysis, mutational frequencies, and aminoglycoside-modifying enzyme assays. Am Rev Respir Dis 1985; 132: 409-16.
25. Hobbie SN, Bruell C, Kalapala S et al. A genetic model to investigate drug-target interactions at the ribosomal decoding site. Biochimie 2006; 88: 1033-43.
26. Pfister P, Hobbie S, Vicens Q et al. The molecular basis for A-site mutations conferring aminoglycoside resistance: relationship between ribosomal susceptibility and X-ray crystal structures. Chembiochem 2003; 4: 1078-88.
27. Shcherbakov D, Akbergenov R, Matt T et al. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 2010; 77: 830-40.
28. De Stasio EA, Moazed D, Noller HF et al. Mutations in 16S ribosomal RNA disrupt antibiotic-RNA interactions. EMBO J 1989; 8: 1213-6.
29. Baudin F, Ehresmann C, Romby P et al. Higher-order structure of domain III in Escherichia coli 16S ribosomal RNA, 30S subunit and 70S ribosome. Biochimie 1987; 69: 1081-96.
30. Apirion D, Schlessinger D. Coresistance to neomycin and kanamycin by mutations in an Escherichia coli locus that affects ribosomes. J Bacteriol 1968; 96: 768-76.
31. Zaunbrecher MA, Sikes RD Jr, Metchock B et al. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2009; 106: 20004-9.
32. Wei J, Dahl JL, Moulder JW et al. Identification of a Mycobacterium tuberculosis gene that enhances mycobacterial survival in macrophages. J Bacteriol 2000; 182: 377-84.
33. Recht MI, Puglisi JD. Aminoglycoside resistance with homogeneous and heterogeneous populations of antibiotic-resistant ribosomes. Antimicrob Agents Chemother 2001; 45: 2414-9.
34. Andersson DI. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 2006; 9: 461-5.